Advanced Renal Cell Carcinoma: Building a Personalized First-Line Treatment Algorithm

Dr. Monty Pal introduces the program by outlining the evolving treatment landscape for advanced renal cell carcinoma (RCC) and emphasizing the importance of translating clinical trial evidence and guideline recommendations into individualized patient care. He explains that while clinical guidelines provide a valuable framework, treatment decisions should be tailored to each patient's clinical presentation rather than relying solely on traditional risk stratification. Dr. Pal describes the key factors that shape his first-line treatment algorithm, including performance status, disease tempo, and overall clinical condition. He discusses how patients with rapidly progressive disease may benefit from an immunotherapy and tyrosine kinase inhibitor combination, whereas those with less aggressive disease may be appropriate candidates for dual immunotherapy. This segment establishes the foundation for the discussion by highlighting the principles that guide personalized treatment selection in advanced renal cell carcinoma and sets the stage for a deeper exploration of sequencing strategies throughout the program.